S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
New CBOE “special perk” helps traders target income every weekend (Ad)
Dozens of animals taken from Virginia roadside zoo as part of investigation
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Cows in Rotterdam harbor, seedlings on rafts in India; are floating farms the future?
Agriculture gets its day at COP28, but experts see big barriers to cutting emissions
New CBOE “special perk” helps traders target income every weekend (Ad)
Shohei Ohtani joins big-money club with massive contract with Los Angeles Dodgers
Consumer product agency issues warning on small magnetic balls linked to deaths
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
New CBOE “special perk” helps traders target income every weekend (Ad)
Dozens of animals taken from Virginia roadside zoo as part of investigation
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Cows in Rotterdam harbor, seedlings on rafts in India; are floating farms the future?
Agriculture gets its day at COP28, but experts see big barriers to cutting emissions
New CBOE “special perk” helps traders target income every weekend (Ad)
Shohei Ohtani joins big-money club with massive contract with Los Angeles Dodgers
Consumer product agency issues warning on small magnetic balls linked to deaths
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
New CBOE “special perk” helps traders target income every weekend (Ad)
Dozens of animals taken from Virginia roadside zoo as part of investigation
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Cows in Rotterdam harbor, seedlings on rafts in India; are floating farms the future?
Agriculture gets its day at COP28, but experts see big barriers to cutting emissions
New CBOE “special perk” helps traders target income every weekend (Ad)
Shohei Ohtani joins big-money club with massive contract with Los Angeles Dodgers
Consumer product agency issues warning on small magnetic balls linked to deaths
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
New CBOE “special perk” helps traders target income every weekend (Ad)
Dozens of animals taken from Virginia roadside zoo as part of investigation
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Cows in Rotterdam harbor, seedlings on rafts in India; are floating farms the future?
Agriculture gets its day at COP28, but experts see big barriers to cutting emissions
New CBOE “special perk” helps traders target income every weekend (Ad)
Shohei Ohtani joins big-money club with massive contract with Los Angeles Dodgers
Consumer product agency issues warning on small magnetic balls linked to deaths

CareDx Stock Price, News & Analysis (NASDAQ:CDNA)

$9.81
+0.08 (+0.82%)
(As of 12/8/2023 ET)
Compare
Today's Range
$9.52
$10.14
50-Day Range
$4.90
$9.88
52-Week Range
$4.80
$18.04
Volume
790,249 shs
Average Volume
1.27 million shs
Market Capitalization
$530.72 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.80

CareDx MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
40.7% Upside
$13.80 Price Target
Short Interest
Healthy
7.53% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.66
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Selling Shares
$19,472 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.82) to ($1.65) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.09 out of 5 stars

Medical Sector

420th out of 932 stocks

Medical Laboratories Industry

10th out of 20 stocks


CDNA stock logo

About CareDx Stock (NASDAQ:CDNA)

CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.

CDNA Stock Price History

CDNA Stock News Headlines

Brokerages Set CareDx, Inc (NASDAQ:CDNA) PT at $13.80
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Stephens & Co. Upgrades Caredx (CDNA)
CareDx, Inc (NASDAQ:CDNA) Q3 2023 Earnings Call Transcript
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
(0.43
CareDx: Q3 Earnings Insights
CareDx Reports Third Quarter 2023 Results
CareDx to Report Third Quarter 2023 Financial Results
CareDx Announces CEO Transition
CDNA, IDYA and INZY are among after hour movers
CareDx: Diversification Strategies Vs. Core Weaknesses
CareDx Inc (1K9.BE)
See More Headlines
Receive CDNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CareDx and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/08/2023
Today
12/09/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/26/2024

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CDNA
Employees
727
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$13.80
High Stock Price Target
$25.00
Low Stock Price Target
$9.00
Potential Upside/Downside
+40.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
6 Analysts

Profitability

Net Income
$-76,610,000.00
Pretax Margin
-30.41%

Debt

Sales & Book Value

Annual Sales
$321.79 million
Book Value
$8.05 per share

Miscellaneous

Free Float
51,826,000
Market Cap
$530.72 million
Optionable
Optionable
Beta
1.36
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Mr. Abhishek Jain (Age 46)
    CFO & Principal Accounting Officer
    Comp: $425.58k
  • Dr. Peter Maag Ph.D. (Age 56)
    Executive Director
    Comp: $43.23k
  • Mr. Alexander L. Johnson (Age 49)
    President of Patient & Testing Services
    Comp: $547.43k
  • Ms. Marica Grskovic Ph.D.
    Chief Operating Officer
  • Dr. Robert N. Woodward Ph.D.
    Chief Scientific Officer
  • Mr. GS Jha
    Senior VP, Chief Information Officer & Chief Information Security Officer
  • Mr. Ian Cooney
    Vice President of Investor Relations
  • Dr. Mickey Y. Kim M.D.
    Senior VP of Corporate Development & Head of Global Product
  • Mr. Jarrod Borkat
    Senior VP and Head of Marketing & Portfolio Operations
  • Ms. Stacey Follon
    Senior VP & Head of Human Resources














CDNA Stock Analysis - Frequently Asked Questions

Should I buy or sell CareDx stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for CareDx in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" CDNA shares.
View CDNA analyst ratings
or view top-rated stocks.

What is CareDx's stock price target for 2024?

6 brokers have issued 12 month price targets for CareDx's shares. Their CDNA share price targets range from $9.00 to $25.00. On average, they predict the company's stock price to reach $13.80 in the next year. This suggests a possible upside of 40.7% from the stock's current price.
View analysts price targets for CDNA
or view top-rated stocks among Wall Street analysts.

How have CDNA shares performed in 2023?

CareDx's stock was trading at $11.41 at the start of the year. Since then, CDNA stock has decreased by 14.0% and is now trading at $9.81.
View the best growth stocks for 2023 here
.

Are investors shorting CareDx?

CareDx saw a decline in short interest in November. As of November 15th, there was short interest totaling 3,890,000 shares, a decline of 13.6% from the October 31st total of 4,500,000 shares. Based on an average daily trading volume, of 957,600 shares, the short-interest ratio is currently 4.1 days. Currently, 7.5% of the shares of the company are sold short.
View CareDx's Short Interest
.

When is CareDx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 26th 2024.
View our CDNA earnings forecast
.

How were CareDx's earnings last quarter?

CareDx, Inc (NASDAQ:CDNA) issued its quarterly earnings results on Wednesday, November, 8th. The company reported ($0.43) earnings per share for the quarter, missing analysts' consensus estimates of ($0.38) by $0.06. The business had revenue of $67.19 million for the quarter, compared to analysts' expectations of $53.14 million. CareDx had a negative trailing twelve-month return on equity of 21.94% and a negative net margin of 30.46%. The firm's revenue was down 15.3% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.32) EPS.

What guidance has CareDx issued on next quarter's earnings?

CareDx updated its FY 2023 earnings guidance on Wednesday, November, 1st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $274.00 million-$278.00 million, compared to the consensus revenue estimate of $255.42 million.

What other stocks do shareholders of CareDx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CareDx investors own include Block (SQ), Roku (ROKU), Exact Sciences (EXAS), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Enphase Energy (ENPH), Johnson & Johnson (JNJ), Activision Blizzard (ATVI) and Alibaba Group (BABA).

Who are CareDx's major shareholders?

CareDx's stock is owned by a number of institutional and retail investors. Top institutional investors include ARK Investment Management LLC (12.33%), Sumitomo Mitsui Trust Holdings Inc. (5.58%), Armistice Capital LLC (3.76%), Kent Lake Capital LLC (2.54%), Jacobs Levy Equity Management Inc. (2.08%) and First Eagle Investment Management LLC (1.86%). Insiders that own company stock include Ankur Dhingra, George Bickerstaff, Grace Colon, Michael Goldberg, Paul Adler, Peter Maag, Ralph Snyderman, Reginald Seeto, Sasha King, Thomas A Thomas and William A Hagstrom.
View institutional ownership trends
.

How do I buy shares of CareDx?

Shares of CDNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:CDNA) was last updated on 12/10/2023 by MarketBeat.com Staff

My Account -